TG Therapeutics (TGTX) Stock Looks Fairly Valued After A 4x Run

TG Therapeutics stock has delivered a very large 3 year gain, yet the current valuation checks point to a more mixed picture rather than a clear bargain or clear excess. After such a move, investors are weighing how much of the recent optimism around the business is already reflected in the share price.

• The share price return over the past 3 years is about 4 times. This places TG Therapeutics among the stronger movers in its peer group over that period and raises the bar for what needs to go right from here.
• Interest around potential takeover scenarios and expectations for higher BRIUMVI driven revenue can support the current valuation. Any setback in BRIUMVI uptake or deal expectations may challenge the share price that has already re rated sharply.
• The stock screens as undervalued on several market multiple checks, yet the overall score of 4 out of 6 points to a mixed picture rather than a simple cheap or expensive label.

The issue now is whether TG Therapeutics stock still offers enough valuation support after its strong multi year run to appeal to investors who are only looking at it today.

Spot other fast moving opportunities with company fundamentals closer to what you want by scanning our curated list of 52 high quality undervalued stocks.

Does TG Therapeutics Look Undervalued on Earnings?

P/E can be a useful cross check for TG Therapeutics because the company is currently profitable and investors are focused on earnings linked to BRIUMVI. The stock trades on a P/E of about 18.2x, which is very close to the Biotechs industry average of around 17.0x. That puts TG Therapeutics near the middle of the sector pack rather than at an obvious premium or discount based purely on a simple industry comparison.

However, the more tailored fair P/E multiple for TG Therapeutics is estimated at about 24.7x, which factors in its specific growth profile, margins, size and risk. Against that yardstick, the current 18.2x implies the market is pricing the stock at a discount to what this framework suggests could be reasonable. Despite the recent takeover speculation and higher 2026 revenue guidance, the P/E still comes in below both the fair multiple and the broader peer average of roughly 43.6x.

On this P/E check, TG Therapeutics stock appears undervalued relative to the earnings multiple implied by its fundamentals and peer group.

See what the numbers say about this price — find out in our valuation breakdown.

The TG Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the TG Therapeutics valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than it is today, and they sit on the company’s Community page. Each narrative links a fair value estimate to a clear story about TG Therapeutics' potential catalysts and risks so you can watch over time which scenario is unfolding.

Community views on TG Therapeutics could hardly be further apart, with some investors focused on expansion potential and others fixated on execution and concentration risk.

Bull case: 19% undervalued

"The planned launch of subcutaneous (subcu) BRIUMVI is a significant upcoming catalyst, as it could unlock access to 35-40% of the anti-CD20 MS market segment currently dominated by self-administered therapies…"

Read the full Bull Case to see why TG Therapeutics could be undervalued

Bear case: 97% overvalued

"The heavy reliance on BRIUMVI for revenue, combined with a narrow commercial portfolio and slow pipeline progression, leaves TG Therapeutics extremely exposed to competitive threats from established branded IV and newer subcutaneous options…"

Read the full Bear Case to see why TG Therapeutics could be overvalued

Do you think there's more to the story for TG Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

TG Therapeutics currently screens as undervalued on earnings multiples, with the P/E sitting below both its tailored fair multiple and the broader peer group. That suggests some valuation support, although the broader checks indicate a mixed picture rather than a clear bargain. After a strong move in the share price, the key question is whether BRIUMVI can deliver the revenue and execution needed to justify even a modest re-rating. The core issue in the debate is whether today’s discount reflects a potential opportunity or an appropriate recognition of concentration and competitive risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com